Know Cancer

or
forgot password

Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study


N/A
18 Years
70 Years
Not Enrolling
Female
Breast Cancer

Thank you

Trial Information

Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study


To demonstrate iodide uptake capacity of breast cancer metastases by imaging women with
iodide radioisotope (123I) and calculating potential ablative dose of radioactive iodide
(131I).


Inclusion Criteria:

- Only women diagnosed with breast cancer

- 18 years of age or older

- From whom informed consent can be obtained

- Patient is able to provide a fluid (e.g. cyst fluid)

- Patient with blood test that shows protein may allow iodide to accumulate in breast
tissue

- Patient who's breast cancer cells accumulated I123 and held on to it for 24 hours

Exclusion Criteria:- Males

- Children

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Principal Investigator

Irene L. Wapnir

Investigator Role:

Principal Investigator

Investigator Affiliation:

Stanford University

Authority:

United States: Institutional Review Board

Study ID:

BRSMTS0002

NCT ID:

NCT00185809

Start Date:

November 2000

Completion Date:

August 2008

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms

Name

Location

Stanford University School of MedicineStanford, California  94305-5317